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Cystic fibrosis (CF) is a common recessive disorder caused by
>1600 mutations in the CF transmembrane conductance regu-
lator (CFTR) gene. About 13% of CFTRmutations are classified
as “splicingmutations,” but for almost 40%of these, their role in
affecting the pre-mRNA splicing of the gene is not yet defined.
In this work, we describe a new splicing mutation detected in
three unrelated Italian CF patients. By DNA analyses and
mRNA studies, we identified the c.1002–1110_1113delTAAG
mutation localized in intron 6b of the CFTR gene. At themRNA
level, this mutation creates an aberrant inclusion of a sequence
of 101 nucleotides between exons 6b and 7. This sequence cor-
responds to a portion of intron 6b and resembles a cryptic exon
because it is characterized by an upstream ag and a downstream
gt sequence, which are most probably recognized as 5- and
3-splice sites by the spliceosome. Through functional analysis
of this splicing defect, we show that this mutation abolishes the
interaction of the splicing regulatory protein heterogeneous
nuclear ribonucleoprotein A2/B1 with an intronic splicing reg-
ulatory element and creates a new recognition motif for the
SRp75 splicing factor, causing activation of the cryptic exon.
Our results show that the c.1002–1110_1113delTAAG muta-
tion creates a new intronic splicing regulatory element in intron
6b of the CFTR gene exclusively recognized by SRp75.
Cystic fibrosis (CF2; MIM entry #219700) is the most fre-
quent severe autosomic recessive disorder in the European
population (1). Indeed, CF affects1 in 2500 births, and1 in
25 individuals are heterozygotes, with marked regional varia-
tions (2). CF is caused by mutations of the CF transmembrane
conductance regulator (CFTR orABCC7; MIM #602421) gene,
which is also involved in a broad spectrum of phenotypes,
including male infertility due to congenital bilateral absence of
the vas deferens (3, 4), disseminated bronchiectasis (5, 6), and
chronic pancreatitis (7, 8). The mutational spectrum of this
disease is made up of1600 different mutations, 98% of which
consist of pointmutations ormicrodeletions/insertions (Cystic
Fibrosis Mutation Database). A significant fraction (13%) of
CFTR mutations are classified as “splicing mutations,” but for
almost 40% of these, their role in affecting the pre-mRNA splic-
ing of the gene is not yet defined.
Splicingmutations act by directly disrupting splice sites or by
creating new ones. Varied levels of alternative splicing have
been detected for some of the splicingmutations (9–11). These
differences are most likely due to different utilization of intra-
genic splicing elements by trans-acting splicing factors (12, 13).
cis-Acting elements required for splicing in mammalian cells
include short and poorly conserved consensus sequences,
which specify the 5-splice site, branch site, and 3-splice site.
The 3-splice site is preceded by a polypyrimidine tract of vari-
able length.
The branch point is typically located 18–40 nucleotides
upstream of the polypyrimidine tract. These splicing signals are
essential but do not contain sufficient information to specify
correct splicing patterns, and they alone cannot be distin-
guished fromnumerous surrounding cryptic splice sites of sim-
ilar strength (14). Their efficient recognition, as well as their
regulated usage, requires sequences within exons and introns
called enhancers and silencers. Pre-mRNAsplicing requires the
interaction of these critical cis-acting sequences with splicing
regulating factors that form the spliceosome. The spliceosome
is a highly complex RNA/protein machine consisting of five
small nuclear RNAs and100 proteins such as the SR (serine/
arginine-rich) proteins and heterogeneous nuclear ribonucleo-
proteins (hnRNPs), allowing the fine-tuning of the splicing
process (15–17).
In classical splicing defects, the cis-acting elements are
mutated, and the effect on splicing can be predicted on the basis
of genomic DNA sequence analysis. However, the effect of
mutations in non-obvious regulatory elements is more difficult
to evaluate directly from genome scanning methodologies.
Patient CFTR mRNA analysis represents a good tool for the
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identification and definition of the pathogenic role of sequence
variations not yet defined and splicing defects causing alterna-
tive products.
In this work, we describe three unrelated Italian patients
affected byCFwhoseCFTRmRNAcontains an insertion of 101
nucleotides between exons 6b and 7 corresponding to a portion
of intron 6b. This sequence resembles a cryptic exon because it
is characterized by an upstream ag and a downstream gt
sequence, which are most probably recognized as 5- and
3-splice sites by the spliceosome. We assume that this anom-
alous transcript is caused by a mutation affecting an intronic
splicing regulatory element that either abolishes or creates
specific protein-binding domains, causing an alteration of the
intronic splicing process. To elucidate the mechanisms in-
volved in the aberrant splicing, we carried out molecular anal-
ysis of intron 6b as well as functional studies.
EXPERIMENTAL PROCEDURES
Patients—This study included three unrelated CF patients of
Italian origin affected by a classical form of CF, with one unde-
finedCF allele. Clinical features of affected individuals included
pancreatic insufficiency, chronic lung disease with Pseudomo-
nas aeruginosa infections, and a sweat test of 60 mmol/liter
Cl. These patients were selected after an extensive second
level molecular screening (i.e. denaturing HPLC analysis and
direct sequencing for searching for point mutations, break-
point PCR, and multiple ligation-dependent probe amplifica-
tion for detection of large deletions) carried out on 441 unre-
lated Italian CF patients. The CF genotype of the three patients
was F508del/unknown, G542X/unknown, and exon 2 deletion
(c.545811_1642186del8108ins182)/unknown (18).
DNA and RNA Analyses—DNA extraction was carried out
according to standard procedures (19). Informed consent was
obtained in all cases before collecting patients’ DNA. Screening
for the most common CF mutations was carried out using
INNO-LiPA CFTR 19, CFTR 17Tn update, and CFTR Italian
regional kits (Innogenetics). Denaturing HPLC and multiple
ligation-dependent probe amplification analyses of all 27 CFTR
exons were carried out to detect unknownmutations as well as
large rearrangements.
Nasal epithelial cells were collected from two of the patients
and from two non-CF control subjects using a Cytobrush. RNA
was extracted using TRIzol LS (Invitrogen). cDNA synthesis
was performed with a high capacity cDNA archive kit (Applied
Biosystems) according to the manufacturer’s instructions. The
cDNAwas amplified in six overlapping fragments as follows: an
initial denaturation step at 95 °C for 12min, followed by touch-
down PCR, decreasing the annealing temperature by 0.5 °C
every cycle for 14 cycles starting at 94 °C for 20 s, 62 °C for 40 s,
and 72 °C for 60 s, followed by 35 cycles of regular PCR at 94 °C
for 20 s, 55 °C for 40 s, and 72 °C for 60 s and a final extension
step at 72 °C for 10 min.
A fragment of 400 bp of intron 6b including themutationwas
amplified with IVS6b primers (forward, 5-CTGGCAGAAC-
CAGGATTCAAA-3; and reverse, 5-TTGGAGTCACTTGT-
GATCCTC-3). Sequencing reactions of both amplified cDNA
and amplified intron 6b were carried out according to the
Sanger dideoxy chain termination method using a BigDye ter-
minator cycle sequencing kit (Applied Biosystems). Sequence
analyses were carried out with ABI PRISM 3100 (Applied
Biosystems).
Minigene Constructs—The wild-type CFTR sequences con-
sisting of an exon 6b-intron 6b-exon 7 cassette (4 kb long)
were obtained by amplifying normal genomic DNA with
exon 6b (forward, 5-CACCATGGATCAGAGAGCTGGG-
AAGATC-3) and exon 7 (reverse, 5-CTGTATTTTGTTT-
ATTGCTCC-3) primers. The forward primer includes a
Kozak translation initiation sequence with an ATG initiation
codon. To enable directional cloning, the forward primer
also contains a CACC sequence at its 5-end. The PCR prod-
uct was then cloned into the mammalian expression vector
pcDNA3.1D/V5-His-TOPO (Invitrogen). By PCR-mediated
site-directed mutagenesis, the mutant construct (i.e. lacking
4 nucleotides in intron 6b) was also created with primers
IVS6b4bpdelfor (5-GTTCTGCACTTGAGAATGAAGCT-
TTTCTGAATTATACA-3), IVS6b4bpdelrev (5-TGTAT-
AATTCAGAAAAGGTTCATTCTCAAGTGCAGAAC-3),
IVS6bWTfor (5-GTTCTGCACTTGAGAATGAAGCTTT-
TCTGAATTATACA-3, and IVS6bWTrev (5-TGTATAA-
TTCAGAAAAGCTTCATTCTCAAGTGCAGAAC-3). We
also created several variants with single nucleotide changes at the
deleted sequence. The oligonucleotides used for the PCR-medi-
atedmutagenesis are available upon request.
Analysis of Minigene Expression—HeLa cells were grown in
Dulbecco’s modified Eagle’s medium. Plasmid DNA was ex-
tracted and purified with a HiSpeed plasmid maxi kit (Qiagen).
Cells were transfected with Lipofectamine 2000 (Invitrogen)
with 3g of each reported plasmid (wild-type andmutants) and
the control empty vector. RNA extraction was performed after
48 h using TRIzol LS, and reverse transcription (RT)-PCR was
done as described above with exon 6b forward and exon 7
reverse primers. All PCR products were sequenced.
RNA Probe Preparation—Two synthetic RNA oligonucleo-
tides, RNA-WT (5-GCACUUGAGAAUGAGAAUAGCUU-
UUCUGAA-3) and RNA-M (5-GCACUUGAGAAUGAA-
GCUUUUCUGAAUUAU-3), were either purchased from
Eurofins MWG Operon (Ebersberg, Germany) or synthesized
by in vitro transcription using T7 RNA polymerase and DNA
oligonucleotide templates:WT, 5-TAATACGACTCACTAT-
AGGGCACTTGAGAATGAGAATAGCTTTTCTGAA-3; and
M, 5-TAATACGACTCACTATAGGGCACTTGAGAATG-
AAGCTTTTCTGAA-3.
HeLa Nuclear Extracts—HeLa nuclear extracts were
obtained using a nuclear extract kit (Active Motif, Rixensart,
Belgium) according to the manufacturer’s instructions.
RNAElectrophoreticMobility Shift Assay andUVCross-link-
ing of Protein and RNA—[-32P]UTP-labeled RNA probes (1
g) were synthesized by in vitro transcription for 60 min at
37 °C and treated with DNase for the same period of time. RNA
probes were incubated with 5.2 mM HEPES-KOH (pH 7.9), 1
mMMgCl2, 0.8 mMmagnesium acetate, 0.52 mM dithiothreitol,
3.8% glycerol, 0.75 mM ATP, 0.5 g/l heparin, and 30 g of
HeLa nuclear extract in a final volume of 20 l for 20 min at
room temperature. Following the addition of 5 l of 50% (v/v)
glycerol and tracking dye, the complexes were resolved on a 6%
polyacrylamide gel (19:1 acrylamide/bisacrylamide ratio) in 75
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mM Tris and 75 mM glycine at 100 V for 3–4 h at 4 °C. the gels
were dried and exposed to X-Omat AR films for 3 h. The UV
cross-linking assay was performed by incubation of the
[-32P]UTP-labeled RNA probes (1  106 cpm/incubation)
with 20 g of HeLa nuclear extract in a 20-l final volume at
30 °C for 15 min. The final binding conditions were 20 mM
HEPES (pH 7.9), 72 mM KCl, 1.5 mM MgCl2, 0.78 mM magne-
sium acetate, 0.52 mM dithiothreitol, 3.8% glycerol, 0.75 mM
ATP, and heparin at a 5 g/l final concentration as a nonspe-
cific competitor. The sampleswere then transferred to thewells
of a human leukocyte antigen plate and irradiatedwithUV light
on ice (0.8 kJ for 10 min). Unbound RNA was digested with 30
g of RNase A by incubation for 37 °C for 30 min. The samples
were run on 8–15% SDS-polyacrylamide gels, followed by
autoradiography.
Immobilization of RNA on Agarose Beads and Binding Assay
(RNA Pulldown)—RNAs were covalently linked to adipic acid
dihydrazide-agarose beads by modification of a published pro-
cedure (20). Ten micrograms of RNA were placed in 400 l of
reaction mixture containing 100 mM sodium acetate (pH 5.0)
and 5mM sodiumm-periodate (Sigma), washed four times with
2 ml of 0.1 M sodium acetate (pH 5.0), and pelleted after each
wash at 300 rpm for 3 min. After the final wash, 300 l of 0.1 M
sodium acetate (pH 5.0) were added to the beads, and the slurry
was thenmixedwith the periodate-treatedRNAand rotated for
16 h at 4 °C. The beads with the bound RNA was pelleted and
washed three times with 1 ml of 2 M NaCl and three times with
1 ml of wash buffer (20 mM HEPES-KOH (pH 7.6), 6% (v/v)
glycerol, 0.1 M KCl, 0.2 mM EDTA, and 0.5 mM dithiothreitol).
The beads containing immobilized RNA were incubated in
650 l of wash buffer containing 600 g of HeLa cell nuclear
extract for 20min at 30 °C. Beads were then pelleted by centrif-
ugation at 1000 rpm for 3 min and washed four times with 1 ml
of wash buffer. After the final centrifugation, the proteins
bound to the immobilized RNAwere eluted by addition of 20l
of 4 protein sample buffer and boiled for 5 min.
ProteinAnalysis—Proteinswere separated on 10%SDS-poly-
acrylamide gels and visualized by silver staining or electro-
blotted onto nitrocellulose membrane and probed with anti-
bodies. Internal sequence analysis of the silver-stained band
excised from the SDS-polyacrylamide gels was performed by
theNurexMALDI time-of-flight identification service (Sassari,
Italy). Briefly, bands were excised from SDS gels and destained
by washing twice with 50% acetonitrile in 5 mM ammonium
bicarbonate and then dried for 30 min in 50% acetonitrile.
Dried pieces of gel were subjected to protein digestion by
trypsin. Mass spectrometric analysis were performed with a
MALDI micro MX spectrometer (Micromass, Manchester,
United Kingdom) equipped with a delayed extraction unit
according to the tuning procedures suggested by the manufac-
turer. Sample was loaded onto the MALDI target using 2 ml of
the tryptic digest mixed 1:1 with a solution of -cyano-4-hy-
droxycinnamic acid (10 mg/ml in 40% acetonitrile and 0.1%
(v/v) trifluoroacetic acid). A peak list was generated with Pro-
teinLynx data preparation using the following parameters:
external calibration with lockmass usingmass 2465.1989 Da of
adrenocorticotropic hormone, background subtract-type
adaptive combining all scans, and performing deisotoping with
a threshold of 5%. A peak list created as described abovewas used
in Mascot using the Swiss-Prot Database (release 54.0, Jan 2008).
Search settings allowed one missed cleavage with the trypsin
enzyme selected, oxidation of methionine as a potential variable
modification, a peptide tolerance of 100 ppm, and taxa human.
Antibodies—Anti-hnRNP A2/B1 monoclonal antibody was
from Sigma. SRp75 was identified using amonoclonal antibody
that recognizes a subset of non-small nuclear RNP splicing fac-
tors (SR proteins) such as SRp75, SRp55, SRp40, and SRp20
(Zymed Laboratories Inc., South San Francisco, CA).
Small Interfering RNA Transfections—Small Interfering RNA
(siRNA) transfections were performed in HeLa cells using Lipo-
fectamineRNAiMAX (Invitrogen).Weused 1MON-TARGET-
plus siRNA (Thermo Scientific).
HeLa cells were plated at 2 105 cells/well in 10-mm2 plates
to achieve 40–50% confluence. The next day, 3 l of Lipo-
fectamine RNAiMAX were combined with 197 l of Dulbec-
co’s modified Eagle’s medium (Sigma), and 100 l of 1 M
siRNA was diluted in a final volume of 200 l of Dulbecco’s
modified Eagle’s medium. The two mixtures were combined
and left for 20 min at room temperature. Finally, this mixture
was added to the cells, which were maintained in 1.6 ml of
Dulbecco’s modified Eagle’s medium. After 24 h, a second
roundof siRNA transfectionwas performed as described above.
Eight hours later, the cells were transfected with 2 g of mini-
genes and 3 l of Lipofectamine 2000. On the 3rd day, HeLa
cells were harvested and divided in two parts for protein and
RNA extractions. RT-PCR of total RNA was performed as
described for the transfection protocol described above.
Nuclear protein extracts were obtained as described above and
analyzed for SRp75 endogenous protein expression by immu-
noblotting using the antibody described above. Tubulin was
used as a protein loading control. Each siRNA treatment was
repeated at least three times.
RESULTS
Transcript Analysis of CF Patients—After an extensive sec-
ond level molecular screening carried out at the DNA level on
441 unrelated Italian CF patients, we selected three patients
with one undefined CF allele. To extend their molecular char-
acterization, we performed an RNA study on the selected
patients. The analysis showed a transcript with an insertion of
101 bp between exons 6b and 7 that resembles a cryptic exon
(Fig. 1). Cryptic or pseudoexons have been shown to be acti-
vated by intron mutations that either create or reinforce splice
sites or create a new branch site (21–25). The 101-bp inserted
sequence is part of intron 6b (from nucleotides 1110 to 1113
upstream of exon 7) and is characterized by an upstream ag and
a downstream gt sequence,which aremost probably recognized
as 5- and 3-splice sites by the spliceosome. Sequence analysis
of this region in the DNA patients showed a 4-bp deletionmost
probably affecting an intronic splicing silencer. The deletion is
located 49 bp downstream and 48 bp upstream of the 5- and
3-ends of the postulated cryptic exon, respectively. Inclusion
of the cryptic exon out of the reading frame is predicted to lead
to the insertion of nine amino acid residues followed by a stop
codon. This means that the CFTR protein produced by this
anomalous transcript should be truncated soon after exon
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6b. According to recommendations for the description of
sequence variants, the name of this new mutation is c.1002–
1110_1113delTAAG (26).
Intronic 4-bp Deletion in the CFTR Gene Affects an Intronic
Splicing Regulatory Element Causing Aberrant Splicing—To
demonstrate that the 4-bp deletion in CFTR intron 6b is the
cause of aberrant splicing, we created two minigenes. We
cloned the wild-type construct, spanning exon 6b, the entire
intron 6b, and exon 7 of the CFTR gene (4 kb long), in a
mammalian expression vector. By site-directed mutagenesis,
we also created amutant construct. HeLa cells were transfected
with each construct (wild-type and mutant) and the control
empty vector. We then performed RNA extraction and RT-
PCR. The analysis showed that the wild-type minigene gener-
ated a transcript in which exons 6b and 7 were efficiently and
accurately spliced, as expected. Conversely, the mutated mini-
gene produced an abnormal transcript showing cryptic exon
inclusion, as we found in the patients (Fig. 2).
4-bpDeletion inCFTR Intron 6bCreates aNewSequencewith
Enhancer Properties (Abolishes a Sequence with Silencer
Properties)—To understand the effects of the mutation on the
efficiency of splicing, we performed three rounds of site-di-
rected mutagenesis at the new sequence GAAGC (M), created
after the GAAT deletion. Point mutations were introduced in
the mutated expression vector (M) and evaluated by the func-
tional splicing assay (Fig. 3). The first round ofmutagenesis,M1
(consisting of the GAA 3 CTT substitution), caused a com-
plete restoration of normal transcripts. Conversely, the two
other rounds of mutagenesis, M2 and M3 (consisting of the
GC 3 CA and AG 3 CT substitutions, respectively), caused
only a partial restoration of normal transcripts. The presence of
a GAA element in that position of intron 6b maybe plays a
critical role in splicing efficiency. In fact, it has been shown
previously that substitutions of adenines with uracils in GAA
elements, as in M1, eliminate their enhancing ability (27).
Probably, for this reason, substitutions in M2 and M3, by
affecting GC nucleotides, have moderate effects on the splic-
ing process. Hence, these results indicate that the c.1002–
1110_1113delTAAG mutation most probably removes or
FIGURE 1. Splicing-processing defect in CFTR intron 6b does not affect canonical splicing regulatory elements. a, RT-PCR products obtained from RNA
patients (P1–P3), the normal control (WT), and the negative control (nc) spanning exons 5–9 show an aberrant splicing event (101-bp insertion). b, sequence
and localization of the CFTR cryptic exon in the patients’ cDNA. The new sequence created by the GAAT deletion, located 49 bp downstream and 48 bp
upstream of the 5- and 3-ends of the cryptic exon, respectively, is underlined.
FIGURE 2. c.1002–1110_1113delTAAG mutation causes aberrant inclu-
sionof thecryptic exon.Shownare the results fromRT-PCRofRNAextracted
fromHeLa cells transfected with either theWT ormutatedminigene. TheWT
minigene generates a transcript in which exons 6b and 7 are efficiently and
accurately spliced. The mutated minigene (M) produces an abnormal tran-
script, showing cryptic exon inclusion, aswe found in the patients (P1–P3). nc,
HeLa cells transfected with the empty vector as a negative control.
FIGURE 3. 4-bp deletion in CFTR intron 6b creates a new sequence with
enhancer properties. Shown is the RT-PCR analysis of HeLa cells transfected
withminigenes carryingWT andmutant (M) constructs andmutantsM1–M3.
Multiple pointmutationsM1–M3were introduced in themutated expression
vector and evaluated by functional splicing assay. M1 mutagenesis com-
pletely restored a correct splicing process; in contrast, M2 and M3 mutagen-
esis caused an alternative splicing process. Only the sequence created by the
c.1002–1110_1113delTAAG mutation resulted in a very high level of cryptic
exon inclusion.
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weakens an element with silencer properties and creates a
sequence with enhancer ability, resulting in a very high level
of cryptic exon inclusion (Fig. 3).
4-bp Deletion Creates New Binding with a trans-Acting
Protein—To identify the trans-acting factors possibly binding
this intronic region, electrophoretic mobility shift assay was
performed. We used in vitro tran-
scribed RNAs including either the
wild-type and mutant sequence.
The RNAs were incubated with
HeLa nuclear extract in the pres-
ence of the nonspecific competitor
heparin. As shown in Fig. 4, the
analysis showed two different
shifted bands. The nature of the
protein(s) that bind(s) to themutant
sequence was then investigated.
Identification of Nuclear Proteins
That Bind toWild-type andMutant
CFTR Intron 6b Elements—UV
cross-linking experiments were
done on wild-type and mutant
CFTR intron 6b. The mutant and
wild-type (WT) sequences were
transcribed in vitro in the presence
of [-32P]UTP, and equal quantities
of labeled transcripts were then
used in a UV cross-linking assay
with HeLa nuclear extracts. Among
the numerous proteins that could be
cross-linked to the labeled RNAs, an
35-kDa band could be observed
only in the WT RNA, and an 75-
kDa band could be observed only in
the mutant RNA (Fig. 5a).
To identify the trans-acting fac-
tors differentially binding to WT
and mutant CFTR intron 6b
sequences, we performed a pull-
down analysis using two synthetic
RNA oligonucleotides containing
either the WT or mutant sequence.
Agarose beads linked to theWTand
mutant RNAs were separately incu-
bated with HeLa nuclear extracts,
and the associated proteins were
analyzed by SDS-PAGE, followed by
silver staining. Comparison of the
binding patterns of the WT and
mutant beads showed that the two
patterns have many bands in com-
mon, but in the molecular mass
range of 30–35 kDa, a protein was
pulled down byWTRNAbut not by
the mutant one. Conversely, at
70–75 kDa, a protein complex was
pulled down by mutant RNA but
not by the WT one (Fig. 5b).
Sequence analysis of the excised bands identified the binding
proteins. The protein binding to the WT sequence is hnRNP
A2/B1. The protein binding to the mutant sequence is SRp75.
These results were confirmed by RNA pulldown experiments.
WT and mutant synthetic RNA oligonucleotides were incu-
bated with HeLa nuclear extracts, and the complexes were
FIGURE 4.Reactivity in electrophoreticmobility shift assay ofHeLanuclear extractswithWTandmutant
labeled RNA oligonucleotides. Different complexes were formed in the presence of the WT or mutant (Mut)
RNA (upper arrows). Competition analysis was done by adding unlabeled RNA oligonucleotides at a 100-fold
molar excess (100M). The lower arrow indicates free nucleic acids.
FIGURE 5. Identification of nuclear proteins regulating the splicing process of intron 6b and involved in
the aberrant splicing caused by the 4-bp deletion. a, UV cross-linking experiments carried out on WT and
mutant CFTR intron 6b.WT andmutant (M) labeled RNAs cross-reactedwith35- and75-kDabands, respec-
tively (arrows). Cross-reaction with the WT and mutant labeled probes was detected on 15 and 8% SDS-poly-
acrylamide gels, respectively. b, silver-stained 10% SDS-polyacrylamide gel of a pulldown analysis in which
HeLa nuclear extracts were incubated with adipic dihydrazide beads derivatized with the target RNAs. The
arrows indicate twobands of35 kDapresent in theWT lane and of70 kDapresent only in theM lane. b lane,
beads not linked to the RNA probes as a negative control. c, binding analysis of hnRNP A2/B1 and SRp75
performedbyWestern blotting after pulldown assay. Binding of SRp55 showed no variations betweenWT and
mutant RNAs.
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resolved by SDS-PAGE, followed by Western blotting using
antibodies hnRNP A2/B1 and SRp75 (Fig. 5c). Binding of the
well known specific factor SRp55 showedno variations between
WT and mutant RNAs even though dedicated bioinformatics
tools such as ESEfinder had suggested its possible involvement
with mutant RNA (Fig. 5c).
hnRNP A2/B1 and SRp75 Overexpression in Transfection
Assays Does Not Modify the Splicing Pattern—To evaluate the
functional significance of the interactions of the splicing factors
in theCFTR intron 6b splicing, bothWTandmutantHeLa cells
were transfected with plasmids coding for hnRNP A2/B1 and
SRp75.Western blotting using the antibodies against the target
proteins was carried out to test the overexpression achieved
(Fig. 6, a and b).
Overexpression of both hnRNP A2/B1 and SRp75 in the WT
cells did not show any variation in the splicing pattern.Moreover,
overexpression of hnRNPA2/B1 in themutant cells and of SRp75
did not modify the slicing pattern (Fig. 6c). These results indicate
that the normal sequence in intron 6b contains a strong splicing
regulating element. In addition, the new intronicmotif created by
themutation shows a strong enhancer activity.
siRNA against SRp75 Affects CFTR Intron 6b Splicing—To
evaluate the functional role of SRp75 in the in vivo splicing of
WT and mutant CFTR intron 6b, we used siRNA against this
splicing factor. We transiently transfected HeLa cells, and the
silencing effects were analyzed by Western blotting using the
antibody against the target protein. HeLa cells transfected with
the corresponding siRNA showed a strong reduction in SRp75
levels (Fig. 7a). At the same time, the splicing pattern was eval-
uated by RT-PCR using total RNA. In the mutant cells, the
siRNA-mediated knockdown of SRp75 resulted in partial res-
toration of CFTR intron 6b splicing. The correct splicing of
intron 6b in the WT cells was not affected by siRNA-mediated
depletion of SRp75 (Fig. 7b).
DISCUSSION
CF is a common recessive disorder caused by 1600 muta-
tions in the CFTR gene. Despite the extensive mutation char-
FIGURE 6.Overexpression of hnRNPA2/B1 and SRp75 inmutant andWT cells does notmodify the slicing pattern. a, Western blot analysis of HeLa cells
showing the overexpression achieved after co-transfection of theWTminigene and hnRNPA2/B1 (lane 1) or theWTminigene and SRp75 (lane 2). Lane 3, HeLa
cells transfectedwith theWTminigene alone. b, Western blot analysis of HeLa cells showing the overexpression achieved after co-transfection of themutated
minigene and hnRNP A2/B1 (lane 4) or themutatedminigene and SRp75 (lane 5). Lane 6, HeLa cells transfected with themutatedminigene alone. The graphs
in a and b show the level of expression of hnRNP A2/B1 and SRp75. The y axes represent –fold changes. Tubulin was used as a protein loading control. S.D. was
not detectable. c, effect of overexpression of hnRNP A2/B1 and SRp75 on the splicing pattern of the WT and mutated (M) minigenes. The WT and mutated
minigenes were transfected alone () or co-transfected () with hnRNP A2/B1 or SRp75. The resulting RT-PCR products were separated on 2% agarose gel.
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acterization work around the world, there is still a substantial
fraction of patients with typical clinical diagnosis of CF but
unknown mutations in the CFTR gene (28). About 13% of
CFTR mutations are termed as affecting the pre-mRNA splic-
ing, but for almost 40% of these, their role in affecting the
pre-mRNA splicing is not yet defined. Genotype screening in
the CFTR gene frequently identifies sequence variations whose
association with the disease phenotype is unclear. In fact, the
pathologic effect of an apparently benign polymorphism is dif-
ficult to assess. For this reason, patient CFTR mRNA analysis
represents a good tool for the identification and definition of
the pathogenic role of sequence variations not yet defined and
splicing defects causing alternative products.
In this study, we have described a new splicing mutation
detected in three unrelated Italian CF patients. The molecular
characterization of these patients was carried out at either the
DNAorRNA level. The splicing defect described here abolishes
the interaction of hnRNP A2/B1 with an intronic splicing reg-
ulatory element and creates a new recognition motif for the
SRp75 splicing factor, causing the activation of a cryptic exon.
To our knowledge, this is the first time that the SR splicing
protein SRp75 has been directly implicated in the creation of a
cryptic exon in the CFTR transcript.
SR proteins (15) are typically involved in positive regulation
of splicing, stimulating splicing by interacting with exonic or
intronic splicing enhancer elements. In contrast, negative reg-
ulation is promoted most frequently by hnRNPs (29), which
function by binding sequences known as exonic or intronic
splicing silencers. Several hnRNPs have been identified as key
splicing repressors. Among these, the hnRNP A1 protein has
been extensively characterized. The first hnRNPA1-dependent
exonic splicing silencer was identified in studies of human
immunodeficiency virus Tat exon 2 repression (30, 31). This
exonic splicing silencer was found to bind hnRNP A1, and
FIGURE 7. In vivo depletion of SRp75 partially restores correct CFTR intron 6b splicing. a, Western blot analysis of HeLa cells transfected with theWT and
mutated (M) minigenes treated with () and without () 1 M SRp75 siRNA. The graph shows the expression SRp75 after siRNA treatment in WT andmutant
cells compared with untreated cells. Tubulin was used as a protein loading control. b, effect of siRNA against SRp75 on the WT and mutated minigenes.
Untreated () and siRNA-treated () HeLa cells were transfected with the mutated and WT minigenes. Two different amounts (1 and 0.4 M) of siRNA were
used. nc, negative control.
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mutations disrupting the exonic splicing silencer prevented
hnRNP A1 binding and allowed enhanced exon 2 splicing.
Despite the abundance in the genome of potential pseudoex-
ons (intronic sequences between 50 and 200 nucleotides in
length with apparently possible 5- and 3-splice sites at either
end), their inclusion does not seem to be a frequent event dur-
ing the normal pre-mRNA processing. It was indeed noted that
many of these non-spliced pseudoexons contain multiple
defects in splicing-controlling regions despite their apparently
good agreementwith real exonic sequences (32). In accordwith
this, three putative splicing silencer motifs have been found to
be enriched in these non-spliced pseudoexons compared with
their surrounding intronic regions (33). This observation is in
agreement with a study that showed that human DNA is par-
ticularly rich in sequences that can inhibit splicing (34).
Many intronic sequences seem to be close to becoming exons
because most of the disease-associated pseudoexon inclusion
events originate from a single activating mutation. This muta-
tion generally involves the ex novo creation of a strong donor or
acceptor site, followed by the subsequent selection of weaker
opportunistic acceptor or donor site sequences. However,
other mechanisms that cause the inclusion of pseudoexon-ac-
tivating mutations may also involve the creation or deletion of
splicing regulatory elements.
There are in fact at least two cases, the-galactosidase A (35)
and ATM (36) genes, in which the creation/deletion of splicing
regulatory elements has been observed to occur. In the ATM
gene, the inclusion of a 65-nucleotide long pseudoexon is the
consequence of a 4-nucleotide deletion in ATM intron 20 that
disrupts a high affinity U1 small nuclear ribonucleoprotein-bind-
ing site locatedwithin the pseudoexon sequence itself. This region
is called the intronic splicing processing element, and its disrup-
tion results in the activation of an immediately upstream cryptic
acceptor site and of a downstream cryptic donor site.
The splicing mutation affecting the CFTR gene described in
this work brings to mind the splicing defect in the ATM gene
described by Pagani et al. (36). In summary, our results indicate
that the c.1002–1110_1113delTAAG mutation creates a new
intronic splicing regulatory element in intron 6b of the CFTR
gene specifically recognized by the splicing factor SRp75. This
acts as enhancer that increases the pseudoexon inclusion dur-
ing the splicing process.
We have established that the basic mechanism affecting
splicing due to mutation is not always obvious and cannot be
simply derived from in silico predictions. The creation of an
intronic splicing enhancer may be a common event in human
pathology and has to be taken into account to assess the phe-
notypic risk in CF patients and to devise new therapies.
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